Austin G Acheson1, Matthew J Brookes, Donat R Spahn. 1. Division of Gastrointestinal Surgery, Nottingham Digestive Disease Centre NIHR, Biomedical Research Unit, Queen's Medical Centre, Nottingham, United Kingdom. austin.acheson@nottingham.ac.uk
Abstract
OBJECTIVE: To determine the effect of allogeneic blood transfusion (ABT) on clinical outcomes in patients with colorectal cancer undergoing surgery. BACKGROUND: Perioperative ABTs may be associated with adverse clinical outcomes. METHODS: Systematic review of the literature with odds ratio (OR) and incidence rate ratio (IRR) meta-analyses of predefined clinical outcomes based on a MEDLINE search. RESULTS: In total, 20,795 colorectal cancer (CRC) patients observed for more than 59.2 ± 26.1 months (108,838 patient years) were included, of which 58.8% were transfused. ABT was associated with increased all-cause mortality OR = 1.72 (95% confidence interval [CI] 1.55-1.91, P < 0.001); I(2) = 23.3% (0-51.1) and IRR = 1.31 (1.23-1.39, P < 0.001), I(2) = 0.0% (0-37.0). ABT was also associated with increased ORs (95% CI, P) for cancer-related mortality of 1.71 (1.43-2.05, P <0.001), combined recurrence-metastasis-death 1.66 (1.41-1.97, P < 0.001), postoperative infection 3.27 (2.05-5.20, P < 0.001), and surgical reintervention 4.08 (2.18-7.62, <0.001). IRR (95% CI, P) was 1.45 (1.26-1.66, <0.001) for cancer-related mortality and 1.32 (1.19-1.46, <0.001) for recurrence-metastasis-death. Mean length of hospital stay was significantly longer in transfused compared with nontransfused patients (17.8 ± 4.8 vs 13.9 ± 4.7 days, P = 0.005). CONCLUSIONS: In patients with colorectal cancer (CRC) undergoing surgery, ABTs are associated with adverse clinical outcomes, including increased mortality. Measures aimed at limiting the use of ABTs should be investigated further.
OBJECTIVE: To determine the effect of allogeneic blood transfusion (ABT) on clinical outcomes in patients with colorectal cancer undergoing surgery. BACKGROUND: Perioperative ABTs may be associated with adverse clinical outcomes. METHODS: Systematic review of the literature with odds ratio (OR) and incidence rate ratio (IRR) meta-analyses of predefined clinical outcomes based on a MEDLINE search. RESULTS: In total, 20,795 colorectal cancer (CRC) patients observed for more than 59.2 ± 26.1 months (108,838 patient years) were included, of which 58.8% were transfused. ABT was associated with increased all-cause mortality OR = 1.72 (95% confidence interval [CI] 1.55-1.91, P < 0.001); I(2) = 23.3% (0-51.1) and IRR = 1.31 (1.23-1.39, P < 0.001), I(2) = 0.0% (0-37.0). ABT was also associated with increased ORs (95% CI, P) for cancer-related mortality of 1.71 (1.43-2.05, P <0.001), combined recurrence-metastasis-death 1.66 (1.41-1.97, P < 0.001), postoperative infection 3.27 (2.05-5.20, P < 0.001), and surgical reintervention 4.08 (2.18-7.62, <0.001). IRR (95% CI, P) was 1.45 (1.26-1.66, <0.001) for cancer-related mortality and 1.32 (1.19-1.46, <0.001) for recurrence-metastasis-death. Mean length of hospital stay was significantly longer in transfused compared with nontransfused patients (17.8 ± 4.8 vs 13.9 ± 4.7 days, P = 0.005). CONCLUSIONS: In patients with colorectal cancer (CRC) undergoing surgery, ABTs are associated with adverse clinical outcomes, including increased mortality. Measures aimed at limiting the use of ABTs should be investigated further.
Authors: Stephen T McSorley; Mark Johnstone; Colin W Steele; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; David Mansouri Journal: Int J Colorectal Dis Date: 2018-12-04 Impact factor: 2.571
Authors: Teresa C Rice; Amanda M Pugh; Charles C Caldwell; Barbara St Pierre Schneider Journal: Crit Care Nurs Clin North Am Date: 2017-06-23 Impact factor: 1.326
Authors: Jeffrey L Carson; Frederick Sieber; Donald Richard Cook; Donald R Hoover; Helaine Noveck; Bernard R Chaitman; Lee Fleisher; Lauren Beaupre; William Macaulay; George G Rhoads; Barbara Paris; Aleksandra Zagorin; David W Sanders; Khwaja J Zakriya; Jay Magaziner Journal: Lancet Date: 2014-12-09 Impact factor: 79.321
Authors: Sam C Wang; Joanne F Chou; Vivian E Strong; Murray F Brennan; Marinela Capanu; Daniel G Coit Journal: Ann Surg Date: 2016-02 Impact factor: 12.969
Authors: Raphael C Sun; Anna M Button; Brian J Smith; Richard F Leblond; James R Howe; James J Mezhir Journal: J Gastrointest Surg Date: 2013-02-20 Impact factor: 3.452